Antihypertensives and COVID-19 Risk; New Heart Failure Treatment Approved

Inbox

x

MPR Daily Dose <editor@email.empr.com> Unsubscribe

Thu, May 7, 3:07 AM (21 hours ago)

to me

If you are having trouble viewing this email, click here.

MUST READS Antihypertensive Medication Use Not Linked to Risk for COVID-19 Farxiga Approved for Heart Failure With Reduced Ejection Fraction Vadadustat Noninferior to Darbepoetin Alfa for Anemia in Patients With Dialysis-Dependent CKD Guidelines Issued for Managing Eosinophilic Esophagitis Inhaled Nitric Oxide Therapy Evaluated in Preterm Neonates With Pulmonary Hypertension COVID-19 Resource Center CME/CE Spotlight Improved Outcomes for Naïve & Heavily Treatment—Experienced HIV Patients AMA PRA Category 1 Credit(s)TM, CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME